EzetimibeThird Party Manufacturing in India

Ezetimibe works by selectively inhibiting the absorption of cholesterol from the small intestine. It targets the Niemann-Pick C1-Like 1 (NPC1L1) protein, which is located on the brush border membrane of intestinal epithelial cells and hepatocytes. This protein plays a critical role in the transport of dietary and biliary cholesterol across the intestinal wall into the bloodstream. By binding to NPC1L1, ezetimibe prevents cholesterol from being taken up by enterocytes, thereby reducing the delivery of intestinal cholesterol to the liver.

This reduction in hepatic cholesterol stores triggers a compensatory increase in the clearance of cholesterol from the blood through upregulation of LDL receptors on liver cells. The result is a significant decrease in low-density lipoprotein cholesterol (LDL-C) levels in the circulation. Ezetimibe does not affect the absorption of fat-soluble vitamins, triglycerides, or bile acids, making it highly selective in its action.

Unlike statins, which inhibit cholesterol synthesis in the liver, ezetimibe targets absorption, providing a complementary mechanism. When used in combination with a statin, ezetimibe produces additive LDL-C lowering beyond what either agent achieves alone. It is well-tolerated and effective for patients who cannot achieve target lipid levels with statin monotherapy or those who are statin-intolerant.

Therapeutic Uses

Ezetimibe is prescribed for the treatment of primary hyperlipidemia, including heterozygous familial and non-familial hypercholesterolemia. It is used as adjunctive therapy to diet and lifestyle modifications to reduce elevated total cholesterol, LDL-C, apolipoprotein B, and non-HDL cholesterol levels in patients with primary hyperlipidemia.

• Primary Hyperlipidemia: Ezetimibe reduces elevated total cholesterol and LDL-C when used alone or in combination with a statin in patients who cannot achieve lipid goals with diet and exercise alone.
• Homozygous Familial Hypercholesterolemia (HoFH): Used in combination with a statin and other lipid-lowering therapies to achieve aggressive LDL-C targets in this severe genetic condition.
• Homozygous Sitosterolemia: Ezetimibe reduces elevated plant sterol levels by blocking their absorption at the intestinal level.
• Cardiovascular Risk Reduction: As demonstrated in the IMPROVE-IT trial, adding ezetimibe to simvastatin therapy in patients with recent acute coronary syndrome provides significant incremental cardiovascular benefit.

Why Manufacturers Choose Ezetimibe

Ezetimibe is one of the most widely manufactured lipid-lowering agents in India due to the high prevalence of dyslipidemia in the population. Indian manufacturers produce ezetimibe as a standalone 10mg tablet and in fixed-dose combinations with rosuvastatin, simvastatin, and atorvastatin. The molecule is ideal for third party manufacturing because of its stable formulation, established safety profile, and consistent demand across domestic and export markets.

Ezetimibe tablets are manufactured under WHO-GMP certified facilities and exported to over 30 countries, making it a staple product for PCD pharma franchise companies and contract manufacturing organizations. Its growing use in combination therapy ensures sustained demand for both the standalone tablet and combination formulations.